1. Home
  2. GPCR vs SPT Comparison

GPCR vs SPT Comparison

Compare GPCR & SPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPCR
  • SPT
  • Stock Information
  • Founded
  • GPCR 2016
  • SPT 2010
  • Country
  • GPCR United States
  • SPT United States
  • Employees
  • GPCR N/A
  • SPT N/A
  • Industry
  • GPCR
  • SPT Computer Software: Prepackaged Software
  • Sector
  • GPCR
  • SPT Technology
  • Exchange
  • GPCR Nasdaq
  • SPT Nasdaq
  • Market Cap
  • GPCR 1.6B
  • SPT 1.9B
  • IPO Year
  • GPCR 2023
  • SPT 2019
  • Fundamental
  • Price
  • GPCR $23.77
  • SPT $28.41
  • Analyst Decision
  • GPCR Strong Buy
  • SPT Buy
  • Analyst Count
  • GPCR 7
  • SPT 14
  • Target Price
  • GPCR $81.29
  • SPT $40.64
  • AVG Volume (30 Days)
  • GPCR 752.3K
  • SPT 587.8K
  • Earning Date
  • GPCR 03-07-2025
  • SPT 02-25-2025
  • Dividend Yield
  • GPCR N/A
  • SPT N/A
  • EPS Growth
  • GPCR N/A
  • SPT N/A
  • EPS
  • GPCR N/A
  • SPT N/A
  • Revenue
  • GPCR N/A
  • SPT $392,402,000.00
  • Revenue This Year
  • GPCR N/A
  • SPT $22.78
  • Revenue Next Year
  • GPCR N/A
  • SPT $14.52
  • P/E Ratio
  • GPCR N/A
  • SPT N/A
  • Revenue Growth
  • GPCR N/A
  • SPT 26.70
  • 52 Week Low
  • GPCR $22.33
  • SPT $25.05
  • 52 Week High
  • GPCR $62.74
  • SPT $65.53
  • Technical
  • Relative Strength Index (RSI)
  • GPCR 37.89
  • SPT 30.24
  • Support Level
  • GPCR $22.33
  • SPT $31.27
  • Resistance Level
  • GPCR $25.17
  • SPT $32.05
  • Average True Range (ATR)
  • GPCR 1.73
  • SPT 1.51
  • MACD
  • GPCR -0.37
  • SPT -0.53
  • Stochastic Oscillator
  • GPCR 15.94
  • SPT 4.02

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.

About SPT Sprout Social Inc

Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. The firm generates majority revenue from software subscriptions.

Share on Social Networks: